Tarsus Pharmaceuticals (TARS) Interest Expenses (2022 - 2026)

Tarsus Pharmaceuticals' Interest Expenses history runs 8 years deep, the most recent figure standing at $2.1 million for Q1 2026.

• In Q1 2026, Interest Expenses fell 3.84% year-over-year to $2.1 million; the TTM figure through Mar 2026 stood at $8.2 million (down 9.35% YoY), while the FY2025 annual figure was $312.6 million, up 73.05% from the prior year.
• Interest Expenses for Q1 2026 stood at $2.1 million, up from $1.6 million in the prior quarter.
• The five-year high for Interest Expenses was $105.7 million in Q2 2025, with the low at $316000.0 in Q1 2022.
• The 5-year median for Interest Expenses is $983000.0 (2024), against an average of $7.5 million.
• Peak annual rise in Interest Expenses reached 4913.51% in 2025, while the deepest fall reached 29.89% in 2025.
• Tarsus Pharmaceuticals' Interest Expenses stood at $692000.0 in 2022, then advanced by 22.25% to $846000.0 in 2023, then soared by 173.29% to $2.3 million in 2024, then decreased by 29.89% to $1.6 million in 2025, then surged by 31.28% to $2.1 million in 2026.
• Business Quant data shows TARS's Interest Expenses at $2.1 million in Q1 2026, $1.6 million in Q4 2025, and $2.3 million in Q3 2025.